结直肠癌与子宫内膜癌MSI/IHC检测及PREMM5风险评分对多基因面板检测致病胚系变异的预测比较
该研究回顾性分析两个单中心队列(高危队列706例,肿瘤门诊队列1058例),比较MSI/IHC与PREMM5模型识别Lynch综合征(LS)及非LS致病胚系变异(PV)的能力。结果显示两者对LS敏感性相当,但MSI/IHC特异性更优;PREMM5对非LS高外显率PV敏感性更优,在MSI/IHC正常者中仍可识别多数高外显率PV携带者。
要点
- MSI/IHC与PREMM5对LS识别敏感性相当,但MSI/IHC特异性显著更高。
- PREMM5对非LS高外显率PV的敏感性优于MSI/IHC。
- MSI/IHC正常但PREMM5≥2.5%者仍应接受多基因面板检测。
核心结论
- MSI/IHC和PREMM5均能有效识别结直肠癌和/或子宫内膜癌患者的LS,但MSI/IHC对LS特异性更好。
- PREMM5可识别非LS高外显率胚系PV,PREMM5评分≥2.5%者(包括MSI/IHC正常者)应提供多基因面板检测。
研究设计与样本
- 回顾性分析两个单中心队列:高危队列706例因遗传评估/检测转诊的结直肠癌和/或子宫内膜癌患者。
- 肿瘤门诊队列1058例连续确诊的结直肠癌患者,未根据家族风险选择。
- 所有参与者均接受胚系多基因面板检测,PREMM5评分根据个人/家族癌症史计算。
主要发现
- 在肿瘤门诊队列中,MSI/IHC与PREMM5对LS携带者的敏感性均为96.6%(P=1.000)。
- 在两个队列中,PREMM5对任何高外显率PV及任何低、中、高外显率PV的敏感性均优于MSI/IHC。
关键数值与推荐
- PREMM5评分≥2.5%被用作阳性阈值。
临床怎么用
- 对结直肠癌和/或子宫内膜癌患者,MSI/IHC可用于LS筛查,但特异性有限。
- PREMM5评分≥2.5%应视为多基因面板检测的指征,即使MSI/IHC正常。
- 临床应结合MSI/IHC和PREMM5以提高LS及非LS遗传性癌症综合征的检出。
局限性
- 回顾性研究设计。
- 两个单中心队列,可能存在选择偏倚。
- 结果需在外部队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor testing for microsatellite instability and/or mismatch repair-deficiency (MSI/IHC) and clinical prediction models effectively screen for Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer (EC), but they have not been assessed for their ability to identify non-LS forms of inherited risk. The aim of this study was to compare MSI/IHC and the PREMM5 prediction model to identify carriers of LS and non-LS pathogenic variants (PVs) among patients with CRC and EC. PATIENTS AND METHODS: Data were retrospectively analyzed from two single-institution cohorts: 706 patients with CRC and/or EC referred for genetic evaluation/testing (high-risk cohort) and 1,058 consecutively ascertained patients with CRC (oncology clinic cohort), unselected for familial risk. All participants underwent germline multigene panel testing. PREMM5 scores were calculated from personal/family cancer history. The primary outcome was the proportion of individuals with germline PVs (LS PVs, high-penetrance PVs, and any PVs) who had abnormal MSI/IHC testing and/or PREMM5 score ≥ 2.5%. RESULTS: MSI/IHC and PREMM5 had comparable sensitivity for identifying LS carriers in high-risk (89.3% v 85.7%; P = .712) and oncology clinic patients (96.6% v 96.6%; P = 1.000), although MSI/IHC had significantly superior specificity for LS (81.3% v 20.1%; P < .001; 92.3% v 24.3%; P < .001). In both cohorts, PREMM5 had superior sensitivity to MSI/IHC at identifying patients with any high-penetrance PVs and any low-, moderate-, and high-penetrance PVs. Among patients with normal MSI/IHC, PREMM5 identified 84.2% and 83.3% of high-risk patients with CRC/EC and oncology clinic CRC patients with high-penetrance PVs, respectively. CONCLUSION: MSI/IHC and PREMM5 effectively identify patients with CRC and/or EC with LS, although MSI/IHC has better specificity for LS. Because PREMM5 identifies non-LS, high-penetrance germline PVs, patients with CRC and/or EC with PREMM5 score ≥ 2.5%, including those with normal MSI/IHC, should be offered multigene panel testing.
引用
- Mannucci A, Furniss CS, Ukaegbu C, et al. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. J Clin Oncol. 2020. PMID: 32997573. doi:10.1200/JCO.20.01470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。